For research use only
| Cat No. | ABC-X0287C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human EML4_ALK (F1174L_G1202R) BAF3 Cell Line is engineered to study ALK fusion double mutations’ effects on lung cancer growth and drug resistance.
Human EML4_ALK (F1174L_G1202R) BAF3 Cell Line is derived from murine Ba/F3 cells with lentiviral transduction of the human EML4-ALK fusion gene carrying F1174L and G1202R double mutations. Cells are expanded below passage 20 and validated by qRT-PCR.
Target
The EML4-ALK fusion is a potent oncogenic driver in lung cancer. F1174L and G1202R mutations co-occur within the ALK kinase domain, conferring strong resistance to first- and second-generation ALK inhibitors. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0287C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This cell line supports investigation of compound ALK inhibitor resistance, kinase structural modeling, and testing of third-generation ALK inhibitors.